Gilead Sciences Patent-Cliff Exposure & CMS Drug Spending Portfolio

Gilead Sciences (Foster City, CA): 34 reconciled FDA prescription therapies, $10.92B 2024 CMS Part D & Medicaid spend, and 70 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterFoster City, CA
Reconciled FDA Portfolio Therapies34
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE Date2031-01-01
2024 CMS Total Public Spend$10.92B
2024 Medicare Part D Spend$6.18B
2024 Medicaid Spend$4.73B
California HCAI SB 17 Filings70 WAC filings (max 26.2% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Gilead Sciences across sibling Meru public-data platforms.